Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial

Stevo Julius, Sverre E. Kjeldsen, Michael Weber, Hans R. Brunner, Steffan Ekman, Lennart Hansson, Tsushung Hua, John Laragh, Gordon T. McInnes, Lada Mitchell, Francis Plat, Anthony Schork, Beverly Smith, Alberto Zanchetti

Research output: Contribution to journalArticle

Abstract

Background The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial was designed to test the hypothesis that for the same blood-pressure control, valsartan would reduce cardiac morbidity and mortality more than amlodipine in hypertensive patients at high cardiovascular risk. Methods 15 245 patients, aged 50 years or older with treated or untreated hypertension and high risk of cardiac events participated in a randomised, double-blind, parallel-group comparison of therapy based on valsartan or amlodipine. Duration of treatment was event-driven and the trial lasted until at least 1450 patients had reached a primary endpoint, defined as a composite of cardiac mortality and morbidity. Patients from 31 countries were followed up for a mean of 4·2 years. Findings Blood pressure was reduced by both treatments, but the effects of the amlodipine-based regimen were more pronounced, especially in the early period (blood pressure 4·0/2·1 mm Hg lower in amlodipine than valsartan group after 1 month; 1·5/1·3 mm Hg after 1 year; p

Original languageEnglish
Pages (from-to)2022-2031
Number of pages10
JournalLancet
Volume363
Issue number9426
DOIs
Publication statusPublished - Jun 19 2004

Fingerprint

Valsartan
Antihypertensive Agents
Amlodipine
Blood Pressure
Morbidity
Mortality
Group Psychotherapy
Hypertension
Valsartan Drug Combination Amlodipine
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Julius, S., Kjeldsen, S. E., Weber, M., Brunner, H. R., Ekman, S., Hansson, L., ... Zanchetti, A. (2004). Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet, 363(9426), 2022-2031. https://doi.org/10.1016/S0140-6736(04)16451-9

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine : The VALUE randomised trial. / Julius, Stevo; Kjeldsen, Sverre E.; Weber, Michael; Brunner, Hans R.; Ekman, Steffan; Hansson, Lennart; Hua, Tsushung; Laragh, John; McInnes, Gordon T.; Mitchell, Lada; Plat, Francis; Schork, Anthony; Smith, Beverly; Zanchetti, Alberto.

In: Lancet, Vol. 363, No. 9426, 19.06.2004, p. 2022-2031.

Research output: Contribution to journalArticle

Julius, S, Kjeldsen, SE, Weber, M, Brunner, HR, Ekman, S, Hansson, L, Hua, T, Laragh, J, McInnes, GT, Mitchell, L, Plat, F, Schork, A, Smith, B & Zanchetti, A 2004, 'Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial', Lancet, vol. 363, no. 9426, pp. 2022-2031. https://doi.org/10.1016/S0140-6736(04)16451-9
Julius, Stevo ; Kjeldsen, Sverre E. ; Weber, Michael ; Brunner, Hans R. ; Ekman, Steffan ; Hansson, Lennart ; Hua, Tsushung ; Laragh, John ; McInnes, Gordon T. ; Mitchell, Lada ; Plat, Francis ; Schork, Anthony ; Smith, Beverly ; Zanchetti, Alberto. / Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine : The VALUE randomised trial. In: Lancet. 2004 ; Vol. 363, No. 9426. pp. 2022-2031.
@article{ff976b1c73324eb3ba8372f8926c7037,
title = "Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial",
abstract = "Background The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial was designed to test the hypothesis that for the same blood-pressure control, valsartan would reduce cardiac morbidity and mortality more than amlodipine in hypertensive patients at high cardiovascular risk. Methods 15 245 patients, aged 50 years or older with treated or untreated hypertension and high risk of cardiac events participated in a randomised, double-blind, parallel-group comparison of therapy based on valsartan or amlodipine. Duration of treatment was event-driven and the trial lasted until at least 1450 patients had reached a primary endpoint, defined as a composite of cardiac mortality and morbidity. Patients from 31 countries were followed up for a mean of 4·2 years. Findings Blood pressure was reduced by both treatments, but the effects of the amlodipine-based regimen were more pronounced, especially in the early period (blood pressure 4·0/2·1 mm Hg lower in amlodipine than valsartan group after 1 month; 1·5/1·3 mm Hg after 1 year; p",
author = "Stevo Julius and Kjeldsen, {Sverre E.} and Michael Weber and Brunner, {Hans R.} and Steffan Ekman and Lennart Hansson and Tsushung Hua and John Laragh and McInnes, {Gordon T.} and Lada Mitchell and Francis Plat and Anthony Schork and Beverly Smith and Alberto Zanchetti",
year = "2004",
month = "6",
day = "19",
doi = "10.1016/S0140-6736(04)16451-9",
language = "English",
volume = "363",
pages = "2022--2031",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Lancet Publishing Group",
number = "9426",

}

TY - JOUR

T1 - Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine

T2 - The VALUE randomised trial

AU - Julius, Stevo

AU - Kjeldsen, Sverre E.

AU - Weber, Michael

AU - Brunner, Hans R.

AU - Ekman, Steffan

AU - Hansson, Lennart

AU - Hua, Tsushung

AU - Laragh, John

AU - McInnes, Gordon T.

AU - Mitchell, Lada

AU - Plat, Francis

AU - Schork, Anthony

AU - Smith, Beverly

AU - Zanchetti, Alberto

PY - 2004/6/19

Y1 - 2004/6/19

N2 - Background The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial was designed to test the hypothesis that for the same blood-pressure control, valsartan would reduce cardiac morbidity and mortality more than amlodipine in hypertensive patients at high cardiovascular risk. Methods 15 245 patients, aged 50 years or older with treated or untreated hypertension and high risk of cardiac events participated in a randomised, double-blind, parallel-group comparison of therapy based on valsartan or amlodipine. Duration of treatment was event-driven and the trial lasted until at least 1450 patients had reached a primary endpoint, defined as a composite of cardiac mortality and morbidity. Patients from 31 countries were followed up for a mean of 4·2 years. Findings Blood pressure was reduced by both treatments, but the effects of the amlodipine-based regimen were more pronounced, especially in the early period (blood pressure 4·0/2·1 mm Hg lower in amlodipine than valsartan group after 1 month; 1·5/1·3 mm Hg after 1 year; p

AB - Background The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial was designed to test the hypothesis that for the same blood-pressure control, valsartan would reduce cardiac morbidity and mortality more than amlodipine in hypertensive patients at high cardiovascular risk. Methods 15 245 patients, aged 50 years or older with treated or untreated hypertension and high risk of cardiac events participated in a randomised, double-blind, parallel-group comparison of therapy based on valsartan or amlodipine. Duration of treatment was event-driven and the trial lasted until at least 1450 patients had reached a primary endpoint, defined as a composite of cardiac mortality and morbidity. Patients from 31 countries were followed up for a mean of 4·2 years. Findings Blood pressure was reduced by both treatments, but the effects of the amlodipine-based regimen were more pronounced, especially in the early period (blood pressure 4·0/2·1 mm Hg lower in amlodipine than valsartan group after 1 month; 1·5/1·3 mm Hg after 1 year; p

UR - http://www.scopus.com/inward/record.url?scp=2942635317&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2942635317&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(04)16451-9

DO - 10.1016/S0140-6736(04)16451-9

M3 - Article

C2 - 15207952

AN - SCOPUS:2942635317

VL - 363

SP - 2022

EP - 2031

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9426

ER -